Meeting
2018 ASCO Quality Care Symposium
Survival gains in multiple myeloma from 2003 to 2014.
Authors
Rafael Fonseca
Mayo Clinic, Phoenix, AZ
Rafael Fonseca, Anupam B. Jena, Desi Peneva, Zoe Clancy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Big Data Studies; Projects Relating to Equity, Value, and Policy
Track
Projects Relating to Equity, Value and Policy,Big Data Studies
Sub Track
Measuring Value and Costs
Citation
J Clin Oncol 36, 2018 (suppl 30; abstr 98)
DOI
10.1200/JCO.2018.36.30_suppl.98
Abstract #
98
Poster Bd #
K5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols.
First Author: Samer Al Hadidi
Poster
2023 ASCO Annual Meeting
Identification of genes encoding targets associated with adverse events in multiple myeloma.
First Author: Xuan Xu
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto